Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020;368:17 de marzo. [Ref.ID 103563]

Taylor P. Did Trump offer CureVac $1bn for COVID-19 vaccine rights?. PMLiVE 2020:16 de marzo. [Ref.ID 103551]

Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]

Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. PLOS Medicine 2019;16:10 de septiembre. [Ref.ID 103247]

Parsons L. After ten long months of waiting, Roche can finally go-ahead with its $4.3bn takeover of gene therapy specialist Spark Therapeutics, following clearance from the Federal Trade Commission in the US. . PMLiVE 2019:17 de diciembre. [Ref.ID 103226]

Taylor P. BMS completes Celgene merger after FTC okay. PMLiVE 2019:18 de noviembre. [Ref.ID 103210]

Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019:10 de mayo. [Ref.ID 103131]

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

Jones G. Orphan drugs market to soar to $224bn by 2024. Cell and gene therapies to fuel growth. PMLiVE 2019:25 de abril. [Ref.ID 103080]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Pinto T. Los nuevos anticoagulantes obligan a las farmacéuticas a pagar cientos de millones para evitar juicios . eldiario.es 2019:31 de marzo. [Ref.ID 103065]

Silverman E. STAT Plus: AbbVie is sued for using Humira patent deals to block competition in the U.S.. STAT Daily Recap 2019:20 de marzo. [Ref.ID 103062]

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM, for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:29 de noviembre. [Ref.ID 102917]

Anónimo. Ocrélizumab et sclérose en plaques. Prescrire 2018;38:890-2. [Ref.ID 102904]

Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, Zhou G-Q, Li W-F, Mao Y-P, Hsu C, Liu Q, Lin A-H, Tang L-L, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:8 de noviembre. [Ref.ID 102847]

Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]

Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]

Anónimo. Atézolizumab et cancer bronchique métastasté ou inopérable. Prescrire 2018;38:503-4. [Ref.ID 102758]

Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]